PharmiWeb.com - Global Pharma News & Resources
23-Mar-2022

Cardiac Biomarker Diagnostic Test Kits Market is projected to expand at 5.1% CAGR over the forecast period 2022 to 2028

According to the latest market report published by the company titled ‘Global Cardiac Biomarker Diagnostic Test Kits: Global Industry Analysis 2013–2021 and Opportunity Assessment, 2021–2028’, the global cardiac biomarker diagnostic test kits market is projected to expand at a CAGR of 5.1% during the forecast period 2021–2028 and reach US$ 2,540.8 Mn by the end of 2028.

Global Cardiac Biomarker Diagnostic Test Kits Market: Dynamics

Chest pain is a common emergency department (ED) presentation accounting for 8–10 million visits per year in the U.S. The increasing number of patient visits in the emergency department is expected to create growth opportunities for the cardiac biomarker diagnostic test kits market. Obesity has become a global health challenge in the past few decades, with every sixth person being obese. According to the WHO, the number of obese population around the globe has doubled in the last two decades.

The growing obese population, which is at a high risk of developing cardiovascular diseases, is expected to consequently increase the demand for cardiac biomarker diagnostic test kits. Moreover, the leading manufacturers of cardiac biomarker diagnostic test kits are focusing on collaborating with universities and associations to develop and expand their product portfolio. On the other hand, less availability of novel cardiac biomarker diagnostic test kits due to tedious approval procedures is expected to hamper the growth of the cardiac biomarker diagnostic test kits market over the next decade.

To remain ‘ahead’ of your competitors, request for a sample @ https://www.futuremarketinsights.com/reports/sample/REP-GB-452

Global Cardiac Biomarker Diagnostic Test Kits Market: Forecast

The global cardiac biomarker diagnostic test kits market is segmented on the basis of product type, indication, end users and regions. On the basis of product type, the cardiac biomarker diagnostic test kits market has been segmented into Brain Natriuretic Peptide (BNPs) Test Kits, Creatine Kinase MB (CK-MB) Test Kits, Troponin (I&T) Tests Kits, Myoglobin Test Kits and other test kits.

By product type, the BNP test kits segment dominated the global cardiac biomarker diagnostic test kits market with market value of US$ 682.9 Mn in 2017, and is expected to be the most lucrative segment throughout the forecast period. The BNP test kits segment in the global cardiac biomarker diagnostic test kits market is also projected to be the fast-growing segment, and to grow at CAGR of 6.8% over 2021–2028.

On the basis of indication, the cardiac biomarker diagnostic test kits market is segmented into Angina Pectoris, Acute Myocardial Infarction, Congestive Heart Failure, and others. By indication, the Angina Pectoris is expected to be the most lucrative segment in the cardiac biomarker diagnostic test kits market, and is estimated to account 45.2% value share in 2018 and to account for 41.4% value share by 2028 end, growing at a CAGR of 3.6%. The congestive heart failure segment by indication is expected to be the fast-growing segment in the cardiac biomarker diagnostic test kits market. The congestive heart failure segment is projected to grow at a CAGR of 6.7% over the forecast period to reach a market value of US$ 357.8 Mn by 2028.

On the basis of end users, the cardiac biomarker diagnostic test kits market has been segmented into hospitals, diagnostic laboratories, outpatient clinics, academic and research institutes. The diagnostic laboratories segment is expected to dominate the global cardiac biomarker diagnostic test kits market in 2018 as a large number of patients visit diagnostic laboratories for the diagnosis of cardiovascular disease. Revenue from the diagnostic laboratories segment is expected to increase at a CAGR of 5.9% over 2021–2028, to reach US$ 997.4 Mn by 2028.

On the basis of region, the cardiac biomarker diagnostic test kits market has been segmented into North America, Latin America, Western Europe, Eastern Europe, Asia-Pacific excluding Japan, China, Japan and Middle East & Africa. North America dominated the global cardiac biomarker diagnostic test kits market with maximum value share in 2017. Chest pain is a common emergency department (ED) presentation in the region accounting for 8–10 million visits per year in the U.S., among which 20% of patients are diagnosed with the help of cardiac biomarker diagnostic test kits for cardiovascular diseases.

One-third share of the cardiac biomarker diagnostic test kits market by value is accounted by the U.S. due to increasing prevalence of cardiovascular diseases and rising adoption of cardiac biomarker diagnostic test kits. APECJ is expected to be the fast-growing regional markets for cardiac biomarker diagnostic test kits due to increasing number of obese population and expansion strategies followed by the key manufacturers in the region. Latin America and MEA are expected to witness sluggish growth in the global cardiac biomarker diagnostic test kits market due to low awareness regarding the benefits of cardiac biomarker diagnostic test kits for the diagnosis of cardiovascular diseases.

Global Cardiac Biomarker Diagnostic Test Kits Market: Competitive Landscape

Examples of some of the key players operating in the global cardiac biomarker diagnostic test kits market are Abbott Laboratories, Danaher Corporation, Bio-Rad Laboratories, Thermo Fisher Scientific, Inc., Becton, Dickinson and Company, F. Hoffmann-La Roche Ltd., Siemens AG, bioMérieux SA, Randox Laboratories Ltd. The global cardiac biomarker diagnostic test kits market is highly fragmented, with top six players, estimated to account for approximately 75% market share.

Abbott Laboratories accounted maximum share of the global cardiac biomarker diagnostic test kits market in 2017, due to the acquisition of Alere Inc., which has helped the company to expand its product portfolio. Acquisition is the key strategy followed by all the leading manufacturers of cardiac biomarker diagnostic test kits market to expand their business. The companies of cardiac biomarker diagnostic test kits market are focusing on acquiring local manufacturers to expand their product portfolio and also to increase their market share.

For critical insights, request for PDF Brochure @ https://www.futuremarketinsights.com/reports/brochure/rep-gb-452

Why Future Market Insights?

• Comprehensive analysis on evolving purchase pattern across different geographies
• Detailed insights of market segments and sub-segments for historical as well as forecast period
• A competitive analysis of prominent players and emerging players in the keyword market
• Detailed information about the product innovation, mergers and acquisitions lined up in upcoming years

Ground breaking research and market player-centric solutions for the upcoming decade according to the present market scenario

About FMI:

Future Market Insights (FMI) is a leading provider of market intelligence and consulting services, serving clients in over 150 countries. FMI is headquartered in Dubai, the global financial capital, and has delivery centers in the U.S. and India. FMI’s latest market research reports and industry analysis help businesses navigate challenges and make critical decisions with confidence and clarity amidst breakneck competition. Our customized and syndicated market research reports deliver actionable insights that drive sustainable growth. A team of expert-led analysts at FMI continuously tracks emerging trends and events in a broad range of industries to ensure that our clients prepare for the evolving needs of their consumers.

Contact Us:

Future Market Insights,
Unit No: AU-01-H Gold Tower (AU), Plot No: JLT-PH1-I3A,
Jumeirah Lakes Towers, Dubai,
United Arab Emirates
MARKET ACCESS DMCC Initiative
For Sales Enquiries: sales@futuremarketinsights.com
Website: https://www.futuremarketinsights.com

Editor Details

Last Updated: 23-Mar-2022